or drug susceptible, defi ned as susceptible to isoniazid, rifampin, and ethambutol and with no known resistance to pyrazinamide (i.e., pyrazinamide susceptible or missing test results). Survival distributions by drug-resistance pattern were estimated by using Kaplan-Meier analysis and compared by using log-rank test statistics. Patient characteristics were compared by using χ 2 tests or, when cell sizes were <5, Fisher exact tests.
Of Figure) . At 24 months, 73.9% of patients with rifampinmonoresistant TB and 40.2% with MDR TB had completed treatment. Treatment duration was shortest for patients with drug-susceptible TB (median 252 days), compared with a median of 274, 555, and 766 days for patients with isoniazid-monoresistant, rifampin-monoresistant, and MDR TB, respectively. Differences in treatment duration based on drug susceptibility were signifi cant (p<0.001) for all comparisons. The MDR TB group included 4 extensively drug-resistant cases (also resistant to any fl uoroquinolone and >1 of the injectable drugs capreomycin, Figure. Treatment duration, by drug-resistance pattern, among reported tuberculosis casepatients who completed treatment, United States, 2006. Cases were among patients who were alive and initiated therapy at diagnosis and who had start and end therapy dates as well as results for initial drug susceptibility testing to isoniazid, rifampin, and ethambutol. Susceptibility testing was conducted on culture-positive Mycobacterium tuberculosis isolates from any specimen type. A color version of this fi gure is available online (wwwnc. cdc.gov/EID/article/18/7/12-0261-F.htm).
kanamycin, or amikacin) (4); no remarkable change in duration of treatment resulted when those 4 cases were removed from analysis.
The surveillance system captures only the initial treatment regimen; thus, we could not assess changes to treatment regimens in response to drug susceptibility test results or treatment nonadherence. We observed no difference in history of prior TB; HIV infection; or miliary, meningeal, pediatric, or bone and joint TB among case-patients with isoniazid-resistant versus drug-susceptible TB (p>0.12 for all comparisons). TB treatment recommendations in the United States emphasize completion within 12 months of initiating therapy, with exceptions for rifampin-resistant TB, meningeal TB, and disseminated disease in pediatric patients (children <15 years of age) (1, 5) . We found no change in treatment duration by drugresistance pattern after removing cases of meningeal TB or cases in children from analysis.
The length of TB treatment duration in the United States has improved since therapy outcomes were fi rst recorded in the National TB Surveillance System in 1993. In our study, 90% of case-patients with drugsusceptible TB completed therapy within 373 days, compared with 671 days in 1993 (6) , and 90% of patients with isoniazid-monoresistant TB completed therapy within 432 days. Although the percentage of MDR TB cases in the United States has declined since 1993, drug resistance remains a serious concern because the percentage of isoniazid-monoresistant TB cases has remained stable (7). Our analysis suggests that despite the effectiveness of rifampin-containing regimens and an apparent lack of clinical differences to justify extending therapy, longer treatment durations persist among patients with isoniazid-monoresistant TB (8) . In our cohort study, <75% of patients with rifampin-monoresistant TB and 40% with MDR TB completed therapy within 24 months, suggesting no improvement since 1993 in the length of treatment duration for rifampin-resistant TB strains (6) .
Exposure of US Travelers to Rabid Zebra, Kenya, 2011
To the Editor: Rabies is an acute progressive encephalitis caused by infection with a lyssavirus (genus Lyssavirus, family Rhabdoviridae) (1) . Most human infections are caused by bites from rabid animals, but the virus also can be transmitted by contact of open wounds or mucous membranes with animal saliva (1,2). Prompt administration of postexposure prophylaxis (PEP) is recommended to prevent rabies (3) . Canids are common sources of human exposures in many regions of Africa, Asia, and Latin America (4). However, all mammals are susceptible, including herbivores such as horses, cattle, and antelope (5-7).
Approximately 16-200 rabies virus exposures occur per 100,000 international travelers (2) . Travelers might be unaware of exposure risks from less commonly affected species because prevention guidelines focus on avoiding contact with feral and wild carnivores (primarily dogs) and bats (2) . After travelers at a safari lodge in Kenya were exposed to a rabid zebra, the Centers for Disease Control and Prevention (CDC) and international partners conducted
